25 Years of Listing
Marked 25 years of listing at National Stock Exchange
Sigrima
India’s first Pertuzumab biosimilar is a groundbreaking advancement in the battle against HER2-positive breast cancer
ZyCoV-D
World’s first Plasmid DNA vaccine to be approved for human use for Covid-19
Ujvira
World’s first biosimilar Antibody Drug Conjugate of Trastruzumab Emtansine, targeting HER2-positive breast cancer.
Oxemia
A breakthrough treatment for Anemia associated with patients suffering from Chronic Kidney Disease (CKD) either on Dialysis or not on dialysis
Nulibry
Acquired through Zydus’ US subsidiary Sentynl Therapeutics Inc, Nulibry is used to treat ultra-rare, life-threatening paediatric genetic disorder, Molybdenum cofactor deficiency (MoCD) Type A, a rare disease
Zydus Lifesciences
A new identity reflecting our evolving mission to impact lives globally.
Bilypsa
First drug to get regulatory approval for MAFLD & MASH anywhere in the world
Zokinvy
First and only treatment for Progeria, a rare and orphan disease, acquired by Zydus’ US subsidiary Sentynl Therapeutics Inc
A Decade of Trailblazing Research
Realising its research-driven vision, Zydus achieved major breakthroughs in NCEs, biologics, and vaccines.
Lipaglyn
India’s first NCE to treat diabetic dyslipidemia.
Exemptia
World’s first biosimilar of Adalimumab
Vivitra, Bryxta
Advanced biosimilars for cancer care.
Twinrab
First-of-its-kind, novel biological entity in the world for treating rabies.
Vaxiflu 4 & ZyVac TCV
Indigenously developed vaccines for public health.
Zydus Wellness acquired Heinz India, emerging as a leader in consumer wellness.
Operational Excellence:
Programmes like Delta, SLIM, and Prism enhanced efficiency.
QUEST was launched to embed a culture of Quality across the organisation.
Achieving the Billion Dollar Dream
With an aggressive innovation strategy and global partnerships, Zydus crossed the billion-dollar milestone.
First-in-India launches and biosimilar partnerships.
Strategic acquisitions expanded access to new markets.
Recognition and accolades followed for pioneering work.
Going Global
Zydus expanded operations across India and ventured into the US, marking its first overseas acquisition. Ranked 4th in Indian pharmaceutical industry rankings.
Restructuring and Strategic Growth
Following a vertical split, Cadila Healthcare Ltd. was born under the brand name ‘Zydus’, embarking on a new growth journey.
Acquired Indon, bolstering pain management therapies.
Launched 23 new products, rising to the Top 10 in industry rankings.
Entered JV with Byk Gulden (Germany) to manufacture Pantoprazole intermediates.
Partnered with Guilin Pharma (China) for anti-malarial Falcigo.
Entered capital markets via IPO, marking a new era of public trust and ownership.
Over 70 years of Trust, Research and Innovation
Building an Indigenous Healthcare Vision
Cadila Laboratories was born with a dream—to provide affordable, high-quality medicines in a newly independent India.
Key Milestones:
LIVIRUBRA
First breakthrough drug to treat pernicious anaemia.
ISOPAR
A unique INH formulation for Tuberculosis.
NEUROXIN-12
Combined B1, B6, B12 in one stable vial for neurological care.
DEXONA
Concentrated Dexamethasone for shock treatment.
BETANASE
Novel anti-diabetic technology recognised with a national award.